回回甘松饮对早期糖尿病肾病大鼠的肾脏保护作用

袁玲; 南一; 徐俊; 吴宥熹; 黄秀兰

doi:10.11653/syfj2014030109

您当前的位置：

首页 >

文章列表页 >

回回甘松饮对早期糖尿病肾病大鼠的肾脏保护作用

更新时间：2024-01-04

- 回回甘松饮对早期糖尿病肾病大鼠的肾脏保护作用
- Protective Effects of Huihui Gansong Yin on Early Stage of Diabetic Nephropathy
- 中国实验方剂学杂志 2014年20卷第3期页码：109-113
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家自然科学基金项目资助（81202774）
- DOI：10.11653/syfj2014030109
  中图分类号：
- 纸质出版日期：2014
- 稿件说明：
移动端阅览
袁玲, 南一, 徐俊, 等. 回回甘松饮对早期糖尿病肾病大鼠的肾脏保护作用[J]. 中国实验方剂学杂志, 2014,20(3):109-113.

YUAN Ling, NAN Yi, XU Jun, et al. Protective Effects of Huihui Gansong Yin on Early Stage of Diabetic Nephropathy[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(3): 109-113.
袁玲, 南一, 徐俊, 等. 回回甘松饮对早期糖尿病肾病大鼠的肾脏保护作用[J]. 中国实验方剂学杂志, 2014,20(3):109-113. DOI： 10.11653/syfj2014030109.

YUAN Ling, NAN Yi, XU Jun, et al. Protective Effects of Huihui Gansong Yin on Early Stage of Diabetic Nephropathy[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(3): 109-113. DOI： 10.11653/syfj2014030109.

摘要

目的：明确回回甘松饮（Huihui Gansong Yin，HGY）对糖尿病肾病大鼠肾脏的保护作用。方法：采用高脂饲料联合链脲佐菌素诱导大鼠实验性糖尿病肾病模型，设正常对照组、模型组、格列喹酮组（10 mg·kg-1）和HGY组（5，10 g·kg-1）。比较给药干预后各组大鼠血清胆固醇（CHO）、甘油三酯（TG）及高、低密度脂蛋白（HDL，LDL）含量；采用酶联免疫吸附方法，检测大鼠糖化血红蛋白A1c（GHbA1c）及尿微量白蛋白（MAU）；分别采用HE染色及PASM染色，光镜下观察肾脏组织的病理变化。结果：与正常对照组比较，模型组大鼠的CHO，TG，LDL，GHbA1c，MAU水平显著上升（P < 0.01），HDL水平显著下降（P < 0.01）。格列喹酮组和HGY组大鼠血脂水平较模型组明显改善（P < 0.01或P < 0.05），GHbA1c及MAU水平均明显低于模型组（P < 0.01），且在降低MAU方面HGY优于格列喹酮（P < 0.01），肾脏病理变化较模型组明显减轻。结论： HGY可改善早期DN大鼠血脂、降低GHbA1c及MAU水平，减轻肾脏病理改变，对早期DN大鼠的肾脏具有一定的保护作用。

Abstract

Objective: To investigate the effects of Huihui Gansong Yin (HGY) on the early stage of diabetic nephropathy. Method: The model of diabetic nephropathy was developed by high-fat diet combined with streptozocin injections. Rats were divided into normal group

model group

glurenorm treatment group(10 mg·kg-1) and HGY treatment group(5

10 g·kg-1).The serum cholesterol(CHO)

triglyceride(TG)

high density lipoproteins(HDL) and low density lipoprotein(LDL) were observed. Enzyme linked immunosorbent assay was used to detect GHbA1c and MAU. The kidneys of rats were harvested for hematoxylin and eosin and the periodic acid-sliver dyeing. The renal lesions were observed under light microscope. Result: Compared with the control group

the level of CHO

LDL

GHbA1c and MAU was significantly increased in the model group(P < 0.01)

while the level of HDL was significantly decreased(P < 0.01). Compared with model group

the levels of blood lipids on the HGY treatment group and glurenorm treatment group were better(P < 0.01 or P < 0.05)

the levels of GHbA1c and MAU were lower(P < 0.01)

meanwhile the HGY treatment group was superior to the glurenorm treatment group on the reduction of MAU. The renal lesions of the HGY and glurenorm treatment groups were lightened than the model group

meanwhile the HGY treatment group was superior to the glurenorm treatment group. Conclusion: HGY may be used to ameliorate blood lipids

decrease the level of GHbA1c and MAU

lessen the pathological of diabetic nephropathy. HGY has protective effects on the early stage of diabetic nephropathy.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

HIF-1α在糖尿病肾病中的机制研究及中医药改善作用的研究进展

保肾方治疗气阴两虚、肾络瘀阻证糖尿病肾病Ⅳ期的随机对照试验

基于EGFR/PI3K/Akt信号通路探讨黄连-麦冬药对延缓糖尿病肾病的作用机制

中药基于NF-κB信号通路干预改善糖尿病肾病的研究进展

大黄糖络丸调控AGEs/RAGE/IKK/NF-κB通路改善糖尿病肾病小鼠肾脏炎症损伤的机制